- Report
- April 2025
- 300 Pages
Global
From €3540EUR$3,995USD£3,049GBP
- Report
- May 2025
- 180 Pages
Global
From €3142EUR$3,545USD£2,705GBP
€3491EUR$3,939USD£3,006GBP
- Report
- July 2025
- 486 Pages
Global
From €5184EUR$5,850USD£4,465GBP
- Report
- July 2025
- 369 Pages
Global
From €5184EUR$5,850USD£4,465GBP
- Report
- July 2025
- 451 Pages
Global
From €5184EUR$5,850USD£4,465GBP
- Report
- June 2025
- 250 Pages
United States
From €2472EUR$2,789USD£2,128GBP
- Drug Pipelines
- March 2021
Global
From €1772EUR$2,000USD£1,526GBP
The Metabolic Drug market is a subset of the Endocrine and Metabolic Disorders Drugs market, which focuses on treatments for diseases related to hormones and metabolism. These drugs are used to treat a variety of conditions, including diabetes, obesity, and thyroid disorders. Metabolic drugs are designed to improve the body's ability to process and use energy, as well as to reduce the risk of metabolic diseases. They can also be used to treat conditions such as hyperlipidemia, hyperglycemia, and hypoglycemia.
The Metabolic Drug market is highly competitive, with a wide range of products available from various manufacturers. Many of these drugs are available over-the-counter, while others require a prescription. The market is also highly regulated, with strict safety and efficacy standards in place.
Some of the major companies in the Metabolic Drug market include Novo Nordisk, Sanofi, Merck, Pfizer, and Eli Lilly. These companies produce a variety of products, including insulin, glucagon-like peptide-1 (GLP-1) agonists, and dipeptidyl peptidase-4 (DPP-4) inhibitors. Show Less Read more